SCHEMBL3540349

SCHEMBL3540349

CC(C)(C)OC(=O)c1cc(F)c(Cl)nc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.57
NFE2L2 Q16236 1/20 0.57
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37
ATR Q13535 1/20 0.36
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRA6 Q16445 1/20 0.34
APP P05067 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
JUN P05412 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538784 0.82 LMNA (0.41) KEAP1NFE2L2POLBAPEX1ATR
SCHEMBL4796423 0.82 KEAP1 (0.41) KEAP1NFE2L2POLBAPEX1ATR
SCHEMBL31459616 0.81 KEAP1 (0.62) KEAP1NFE2L2NFKB1NFKB2RELA
SCHEMBL113592 0.81 KEAP1 (0.62) KEAP1NFE2L2NFKB1NFKB2RELA
SCHEMBL3759627 0.78 APP (0.41) APPHSP90AA1
SCHEMBL2919867 0.77 KEAP1 (0.57) KEAP1NFE2L2POLBCA12CA1
SCHEMBL860929 0.77 KEAP1 (0.57) KEAP1NFE2L2CA12CA1CA2
SCHEMBL23414465 0.76 S1PR3 (0.44) KEAP1NFE2L2ATRAAK1CA12
SCHEMBL13053992 0.76 NPC1 (0.39) KEAP1NFE2L2ATRGABRA1GABRG2
SCHEMBL364791 0.75 POLB (0.40) POLBAPEX1GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024012519-A1 PAN-KRAS INHIBITOR 北京华森英诺生物科技有限公司 2024-01-18 WO disclosed
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SPARCBIO LLC 2023-01-26 US disclosed
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SPARCBIO LLC 2023-01-26 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-7829586-B2 Aryl-substituted nitrogen-containing heterocyclic compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-11-09 US disclosed
US-20090275617-A1 Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds MSD K.K. (JP) 2009-11-05 US disclosed
EP-1935881-A1 ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275617-A1 Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds OPRL1, NPSR1, NPBWR1 KEAP1 1445/4885NFE2L2 1309/4885POLB 4463/4885
US-20100298221-A1 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF NAPRT, PNPO, FABP3 KEAP1 2275/4885NFE2L2 573/4885POLB 2202/4885
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS KEAP1 234/4885NFE2L2 2345/4885POLB 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.